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Recombinant porcine growth hormone (rPGH) solubilized from bacterial inclusion bodies (IBs) using a cationic surfactant was oxidized to form 
disulphide bonds in a simple buffer solution containing 2-mereaptoethanol within an empirically derived optimal molar ratio of 2-mercaptoetha- 
nol:protein. A final yieid of 55% monomeric rPGH was achieved at protein concentrations of up to 5 mg/ml without the need for removal of the 
2-mercaptoethartol or the use of chaotrophic agents. In the absence of 2-mercaptoethanol only 15% rnonomeric rPGH was obtained, with the 
majority forming higher molecular weight aggregates. Using the procedure derived for porcine growth hormone, it may be possible to obtain high 
yields of native protein and overcome the need for using low protein concentrations and chaotrophie agents during in vitro refolding of other 
disulphide bonded recombinant proteins. 
Aggregation; Growth hormone; Mercaptoethanol; Recombinant; Refolding 
1. INTRODUCTION 
Problems of aggregation and/or insolubility com- 
monly encountered due to aberrant (non-native) disul- 
phide bonding during the in vitro refolding procedures 
used to oxidize intra-disulphide bonded proteins have 
meant hat yields of correctly refolded protein are ge- 
nerally low [I-4]. Various refolding protocols of differ- 
ing complexity have been attempted to overcome these 
difficulties [3,5-7]. However, there appear to be no 
simple generally applicable means of obtaining high 
yields of recombinant biologically active disulphide 
bonded proteins. The degree of aggregation of recom- 
binant proteins during in vitro refolding is generally 
controlled by using denaturants (3-5 M Urea or I-2 M 
GnHC1) and by reoxidizing at very low protein con- 
centrations, of the order of 1-100 gg/ml [3,5,8]. These 
constrains often pose serious problems, particularly 
during industrial scale production of relatively low 
value, high volume products such as animal growth 
hormones. The results reported here use 2-mercaptoe- 
thanol as a simple means of creating an optimal in vitro 
environment to form native disulphide bonds by air 
oxidation. Reoxidation of disulphide bonded recom- 
binant proteins within an empirically optimized, nett 
reducing environment, may provide a relatively simple 
means of controlling the significant problem of aggrega- 
tion during in vitro refolding. 
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2. EXPERIMENTAL 
2. I. Solubilization of rPGtt 
Methionyl rPGH derived from plasmid pMG93 was expressed in 
E. coli as described in UK Patent No. 8701848. The resultant IBs were 
solubilized using the cationic surfactant cetyltimethylammonium chlo- 
ride (CTAC; ICI Australia Pty). Briefly, IBs were isolated by cell 
disruption, harvested by differential centrifugation and washed with 
0.1 M citric acid, 0.2 M disodium phosphate pH 4.0 (2 x) and distilled 
H20 (2 ×) prior to use. IBs were used immediatdy or stored at pH 5 
to 6.0 in a nitrogen-purged atmosphere. Approximately 50 mg of IBs 
(117 mg/ml dry weight) was solubilised at 10 mg/ml in a solution of 
0.1 M Tris-HCl, pH I0.0, containing 2% mercaptoethanol (v/v) and 
5% (w/v) CTAC for 1 h at 55°C. Tl]e solubilised inclusion bodies were 
clarified by centrifugation (I0 000 xg, 5 rain) and the supernatant 
fraction immediately mixed with 8 bed volumes of Dowex 50W x 4 
(100-150) mesh) ion exchange resin (Dow Chemical Corporation, 
USA) equilibrated in 0.1 M Glycine-HCl and 5 M urea, pH 10.0 (See 
Australian Patent Applications 11 412 and 15 010) to obtain surfac- 
rant free soluble rPGH. 
2.2. Refolding of rPGH 
Solubilised surfactant-free rPGH (1.5 mg/ml, based on dry weight 
of IBs) was dialysed against 20 mM ethanolamlne-HCl, pH I0.0, for 
24--36 h in order to initiate oxidation of disulphides (refolding). For 
refolding in 2-mercaptoethanol, rPGH was exchanged using G-25 
sephadex gel filtration (PD-10, 'desalting' columns; Pharmacia-LKB) 
into a solution of 20 mM ethanolamine-HCl, pill0.0, containing final 
concentrations of 5, 45, 55, 75 and 100 mM 2-mercaptoethanol. Re- 
folding was for 24~,8 h with shaking in an aerated environment a  
4oc. 
2.3. HPLC Analysis 
RP-HPLC was performed using CI alkyl-bonded silica columns 
(TSK-TMS 250, Toyo Soda Manufacturing Co., Tokyo, Japan; ob- 
tained through Pharmacia - LKB (Australia) Pty. Ltd.). Elution was 
performed at a flow rate of 0.5 ml/min at room teml~rature with 
water/acetonitrile mixtures containing 0.1% (v/v) trifluoroacetic acid 
(TFA) as modifier. A stepwise linear gradient was constructed as 
follows: 100% buffer A (0.1% TFA in dH~O) to 40% buffer B (100% 
Published by Elsevier Science Publishers B.V. 187 
Volume 292, number  1,2 FEBS LETTERS November 1991 
(a) 
OXl01~EO (311 
MONOMI~II (~6%) 
= kd  
~ 42.7  31.15 21.5 
14.4  
. . . . . . . .  . . - - - -  r~ ' '~ ' l~  
(b) 
~tFrDUCED GH 
),IONOMER (96~) 
m--SOLVENT FRONT 
1 2 3 
. . . .  ~ • 
.~. . . - . .  
i ]  
'll 
' i '1 i 
(c) 
GH AGGREGATE (60"~) 
OXIDISRO GH 
MO~OME;I  |1~%)--*- 
1 2 
Fig. I. RP-HPLC and 15% SDS-PAGE analyses comparing various 
purified 'standard' rPGH preparations and rPGH refolded without 
2-mercaptoethanol. (a) RP-HPLC and SDS-PAGE analysis era puri- 
fied monomeric rPGH 'standard'. The rPGH is 96% pure by HPLC 
and has an M~ of 21.5K by SDS-PAGE. (b) RP-HPLC and SDS- 
PAGE analysis of reduced rPGH 'standard' prepared by treating the 
sample in Ca) with 2% (v/v) 2-mercaptoethanol for 1 h in 3.0 M urea. 
(SDS-Gel: lane I, purified rPGH: lane 2, reduced rPGH standard; lane 
3. 'mol.wt.' markers.) Note that the correctly disulphide bonded (mo- 
nomeric) and the reduced rPGH preparations are clearly resolvable 
by their respective retention times on RP-HPLC (typically retention 
times differ by I rain) and by mobility on SDS-PAGE. (c) Solubilized 
rPGH rcfolded in the absence of 2-mercaptoethanol and analysed by 
RP-HPLC and SDS-PAGE. The species corresponding to oxidized. 
momomeric rPGH can be clearly identified as a peak (I 5% of protein) 
eluting with the same retention time ~s the purified rPGH 'standard' 
(cf. Fig. In) and with the same mobility on SDS-PAGE (cf. Fig. In, 
lane I). The other major eluting protein species (80% of protein) with 
a peak retention time typically 1.5-2.0 rain - greater than monomer, 
corresponds to a polydisperse 'aggregated'. that is, inter-molecular 
disulphide bonded rPGH of varying molecular weight on SDS-PAGE 
(lane 1, refolded rPST', lane 2. purified 'standard' rPGH). 
acetonitrile, 0,1% TFA) in 10 rain: 40% buffer B to 70% buffer B in 
15 rain; and to 100% buffer B in 5 rain. The 100% acetonitrile. 0.1% 
TFA eluent was maintained for tl further 0.5 rain before re-equilibra- 
lion, prior to the next injection. 
3. RESULTS AND DISCUSSION 
3.1. Re[biding of rPGH #2 aqueous olutio, 
rPGH refolded against 20 mM ethanolamine.HCl, 
pH 10.0, was ~malysed by RP-HPLC to quantitate the 
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proportion of correctly disulphide bonded (i.e. mono- 
meric, 21.5K rPGH) as a percentage of the total mono- 
mer and 'aggregated' forms. From the results hown in 
Fig. Ic approximately 15% of the rPGH was judged as 
monomerie after refolding. Approximately 80% existed 
as a polydisperse 'aggregate' species as judged by RP- 
HPLC and SDS-PAGE. No reduced rPGH was de- 
tected. 
3.2. Refolding of rPGH in the presence of 2-mercaptoet- 
hanoi 
Samples of rPGH refolded in various concentrations 
of 2-mercaptoethanol were analysed by RP-HPLC. The 
yields ofmonomeric rPGH as a percentage of total peak 
area were respectively: 12% in the presence of 5 mM- 
mercaptoethanol; 25% in the presence of 45 mM 2- 
mercaptoethanol; 28% in the presence of 75 mM 2- 
mercaptoethanol, and 24% in the presence of I00 mM 
2-mercaptoethanol (results not shown). The other 
major forms of rPGH present after refolding in 45-65 
mM 2-mercaptoethanol c mprised a major reduced 
species and a lesser proportion of the 'aggregated' 
species. The presence of these forms of rPGH was con- 
firmed by SDS-PAGE. 
Representative r sults comprising RP-HPLC and 
SDS-PAGE analysis of rPGH refolded in the optimal 
2-mercaptoethanol concentration, 55raM, are shown in 
Fig. 2. In addition to 28% oxidized monomeric rPGH, 
note the significant proportion of reduced (33%) rPGH 
in contrast o the results shown in Fig. Ic where the 
majority (80%) of the rPGH existed as a polydisperse 
aggregate population. 
3.3. Effect of prote& concentration on yieM of monomer 
dur#~g refolding in 2-meycaptoethanol 
rPST at protein concentrations of 1.5-7.5 mg/ml was 
refolded in 55 mM 2-mercaptoethanol and yield of mo- 
nomeric rPGH estimated by RP-HPLC. Yields of 28%, 
38% and 27% respectively for rPGH refolded at 1.5, 3.5 
and 7.5 mg/mi were obtained (results not shown). As 
observed previously, the residual non-monomeric 
rPGH existed mainly as a reduced and lesser 'aggregat- 
ed species'. Clearly, to maximise yield, both the respec- 
tive concentrations of protein and 2-mercaptoethanol 
are required to be controlled uring refolding, although 
surprisingly, higher yields of monomer were obtained at 
elevated prorein concentrations. 
3.4. Secomlary oxidationh'efolding of rPGH 
The results described above demonstrated the need 
for a critical ratio of [protein]:[2-mercaptoethanol] dur- 
ing refolding in order to increase yield of monomer at 
the expense of undesirable 'aggregated' forms. How- 
ever, the presence of significant residual reduced rPGH 
(33%, cf. Fig. 2) even after 48 h of refolding in 55 mM 
2-mercaptoethanol (irrespective of protein concentra- 
tion) suggested that an additional oxidation step in the 
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Fig. 2. Results of RP-HPLC and 15% SDS-PAGE analysis of rPGH 
at 1.5 mg/ml refolded in 55 mM 2-mercaptoethanol. The identity of 
the oxidized monomeric (28% of protein), reduced (33%) and 'aggre- 
gated' species of rPST was established from Fig. 1 and conlimled by 
SDS-PAGE (lane I, rPGH refolded in 55 mM 2-mercaptoethanol; 
lane 2, purified 'standard' rPST; lane 3, reduced rPGH; lane 4, mol.wt. 
markers). 
absence of 2-mercaptoethanol might increase the final 
yield of monomeric rPGH above 38%. Final yields of 
approximately 55% monomeric rPGH were obtained 
after secondary oxidation as judged by RP-HPLC (Fig. 
3). The remaining rPGH (40%) was present as polydis- 
perse aggregates as confirmed by SDS-PAGE (Fig. 3, 
lane 1 ). 
4. CONCLUSION 
The results reported in this study show yields of up 
to 55% monomeric rPGH at protein concentrations of
3-5 mg/ml in the absence of denaturants such as urea 
or GnHCI. These results are comparable to those 
claimed for rPGH refolded at low concentrations in
urea [9] and represent, at least for rPGH, several signif- 
icant departures from the current general dogma's for 
refolding recombinant proteins [1,5]: (i) high yield re- 
covery of native recombinant growth hormones and 
most other recombinant proteins has almost invariably 
necessitated using appropriate concentrations of chao- 
trophic agents during refolding, and (ii) refolding of 
recombinant proteins at concentrations of 1 mg/ml or 
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Fig. 3. Results of RP-HPLC and SDS-PAGE analysis of rPGH fol- 
lowing secondary oxidation (refolding). The rPGH at 3.5 mg/ml was 
refolded for 2411 to obtain a yield of 38% monomer and approximately 
30% residual reduced species, and subsequently exchanged via dialysis 
into 20 mM ethanolamine-HCl containing 50 mM CuCI2 for 24 h with 
aeration. Final yield of rPGH monomer was 55% by HPLC. SDS- 
PAGE gel (lane 1, rPGH after secondary efolding; lane 2, rPGH after 
primary refolding in 55 mM 2-mercaptoethanol; lane 3, purified 
'standard' rPGH; lane 4, reduced 'standard' rPGH and lane 5, tool. 
wt. markers). Note the absence of reduced rPGH in lane I. 
less (commonly I-I00 gg/ml) has been necessary to 
maximize yields of native protein. Surprisingly, using 
2-mercaptoethanol, we observed an inverse relationship 
between yield of monomer and concentration f protein 
during refolding, up to a value of 5 mg/ml. 
Clearly, the maintenance of a critical ratio of 2-mer- 
captoethanol:protein during disulphide bond formation 
provides an optimized in vitro environment that signif- 
icantly lessens rPGH aggregation via otherwise undesir- 
able intermolecular disulphide bonding. Moreover, the 
formation of the 'correct' disulphide bonds via air oxi- 
dation, occured without he necessity of removal of the 
2-mercaptoethanol, where previously in the literature 
formation of protein disulphide bonds from the reduced 
state has involved substantially complete removal of 
reducing agent. It is interesting to consider whether the 
use of a nett reducing environment via a critical 2- 
mercaptoethanol:protein ratioduring refolding will be 
generally applicable to the simplified and high yield 
recovery of the native forms of other disulphide bonded 
recombinant proteins. 
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